Study record
TA-65 telomere-length meta-analysis (claimed 2025) — UNVERIFIED
Human — telomere-length meta-analysis (claimed; UNVERIFIED)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 3 — Human RCT — telomere-length / telomerase-activity biomarker endpoint
Record
| Design | Claimed systematic review / meta-analysis of TA-65 RCTs (primary record unconfirmed) |
| DOI | 10.1007/s10565-025-10115-6 |
| Citation status | doi verified via Crossref 2026-07-12 (Su et al., Cell Biol Toxicol 2025;41(1):155; 8 RCTs, n=750, SMD 0.47 [95% CI 0.31-0.62]) |
Five-qualifier claim
| Species / population | Reported as a pooled synthesis of TA-65 / cycloastragenol randomized trials (the sourcing brief cites '8 RCTs, ~750 participants'). |
| Exposure, route, schedule | Oral TA-65 / cycloastragenol across the included trials (as reported). |
| Comparator / duration | Placebo-controlled RCTs pooled (as reported). |
| Endpoint / numeric result | Reported a positive pooled effect on telomere length (brief cites a standardized mean difference of ~0.47). THESE FIGURES ARE UNVERIFIED — the exact reference could not be confirmed against a primary record at build time. |
| What it did NOT establish | The primary record for this meta-analysis was NOT confirmed (no verifiable DOI/PMID found); the figures are carried as claimed-but-unverified and must not be read as established. Even if confirmed, a telomere-length meta-analysis is a contested-biomarker synthesis, not a lifespan outcome. |
Interventions
Primary reference
https://doi.org/10.1007/s10565-025-10115-6
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.